Product Development
Device labeling is one of the most regulated aspects of a medical device — and one of the most commonly cited 483 observation categories. Labeling submitted with a 510(k) or PMA must reflect the cleared or approved indication exactly, comply with 21 CFR Part 801, and survive human factors review.
Review Your LabelingLabeling Strategy
Under 21 CFR Part 801, medical device labeling must include the device name, the name and place of business of the manufacturer or distributor, an adequate directions for use statement, and any required warnings. Additional requirements apply by device type, by classification, and by the cleared or approved indication for use. For prescription devices under 21 CFR 801.109, adequate directions for use may be satisfied by directions to licensed practitioners rather than lay users — but the prescription labeling requirements still require specific content elements including the device name, intended use, and contraindications.
The most common labeling compliance gap we see is an intended use statement on the device label or in the IFU that does not exactly match the indication for use cleared in the 510(k) or approved in the PMA. Expanding, narrowing, or rephrasing the cleared indication in labeling is a regulatory action — it requires a new submission or a supplement, depending on the significance of the change. Using marketing language in labeling that implies uses beyond the cleared indication constitutes misbranding and off-label promotion. We review all labeling against the cleared or approved indication before commercialization.
The Instructions for Use (IFU) must satisfy 21 CFR 801 requirements and FDA's human factors expectations simultaneously. From a compliance standpoint, the IFU must provide adequate directions for use — meaning that under customary conditions of purchase and use, a layperson could use the device safely and for the purpose intended. From a human factors standpoint, the IFU is part of the user interface and must be evaluated for clarity, reading level appropriateness, and usability — particularly for critical tasks where misunderstanding could cause harm.
We write IFUs to both standards. The document structure follows industry-standard device IFU conventions with explicit sections for intended use, contraindications, warnings and precautions, instructions, and troubleshooting. Language is validated against the expected user population's reading level. Where the device category has specific IFU guidance documents (FDA guidance on labeling for specific device types), we apply those guidelines explicitly.
Medical device labels commonly use ISO 15223-1 symbols to communicate information in multiple-language markets. FDA's recognition of ISO 15223-1 symbols (FDA guidance on symbol use) permits their use in US device labeling as long as the symbol is on the recognized symbol list or is accompanied by a reference to the standard. Using symbols not on the recognized list without the standard reference creates a labeling deficiency. We maintain current knowledge of FDA's accepted symbol list and apply symbols consistently with the requirements.
UDI labeling requirements under 21 CFR Part 830 require that device labels include the device identifier (DI) in human-readable and AIDC (barcode or RFID) format, along with the production identifier (PI) elements specified by device class. Compliance dates vary by device class, and GUDID database registration is required. We assess UDI labeling compliance and support GUDID registration as part of labeling development.
Get Started
Device labeling is reviewed during FDA submissions and inspected during facility audits. Labeling that doesn't match the cleared indication, omits required elements, or uses unauthorized symbols creates regulatory exposure at both points.